346 related articles for article (PubMed ID: 9177359)
1. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.
Sih R; Morley JE; Kaiser FE; Perry HM; Patrick P; Ross C
J Clin Endocrinol Metab; 1997 Jun; 82(6):1661-7. PubMed ID: 9177359
[TBL] [Abstract][Full Text] [Related]
2. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.
Page ST; Amory JK; Bowman FD; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
J Clin Endocrinol Metab; 2005 Mar; 90(3):1502-10. PubMed ID: 15572415
[TBL] [Abstract][Full Text] [Related]
3. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.
Hajjar RR; Kaiser FE; Morley JE
J Clin Endocrinol Metab; 1997 Nov; 82(11):3793-6. PubMed ID: 9360543
[TBL] [Abstract][Full Text] [Related]
6. Effects of testosterone replacement in hypogonadal men.
Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
[TBL] [Abstract][Full Text] [Related]
7. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
Leder BZ; Rohrer JL; Rubin SD; Gallo J; Longcope C
J Clin Endocrinol Metab; 2004 Mar; 89(3):1174-80. PubMed ID: 15001605
[TBL] [Abstract][Full Text] [Related]
8. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease.
Tan RS; Pu SJ
Aging Male; 2003 Mar; 6(1):13-7. PubMed ID: 12809076
[TBL] [Abstract][Full Text] [Related]
9. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
11. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections.
Rochira V; Balestrieri A; Madeo B; Granata AR; Carani C
J Androl; 2006; 27(2):165-75. PubMed ID: 16278367
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
Cunningham GR; Ellenberg SS; Bhasin S; Matsumoto AM; Parsons JK; Preston P; Cauley JA; Gill TM; Swerdloff RS; Wang C; Ensrud KE; Lewis CE; Pahor M; Crandall JP; Molitch ME; Cifelli D; Basaria S; Diem SJ; Stephens-Shields AJ; Hou X; Snyder PJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6238-6246. PubMed ID: 31504596
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG
J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial.
Seidman SN; Spatz E; Rizzo C; Roose SP
J Clin Psychiatry; 2001 Jun; 62(6):406-12. PubMed ID: 11465516
[TBL] [Abstract][Full Text] [Related]
17. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.
Burnett-Bowie SA; Roupenian KC; Dere ME; Lee H; Leder BZ
Clin Endocrinol (Oxf); 2009 Jan; 70(1):116-23. PubMed ID: 18616708
[TBL] [Abstract][Full Text] [Related]
18. Testosterone supplementation therapy for older men: potential benefits and risks.
Gruenewald DA; Matsumoto AM
J Am Geriatr Soc; 2003 Jan; 51(1):101-15; discussion 115. PubMed ID: 12534854
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
20. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
